(Q41927602)

English

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial

scientific article published on 29 November 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

hydroxychloroquine

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ronald van Vollenhoven

6

object named as

Ronald F van Vollenhoven

0 references

author name string

Johan A Karlsson

1

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Martin Neovius

2

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Jan-Åke Nilsson

3

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Ingemar F Petersson

4

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Johan Bratt

5

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Sofia Ernestam

7

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Pierre Geborek

8

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

language of work or name

0 references

publication date

29 November 2012

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

72

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

1927-1933

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

EuroQol: the current state of play

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Limited correlation between the Health Assessment Questionnaire (HAQ) and EuroQol in rheumatoid arthritis: questionable validity of deriving quality adjusted life years from HAQ.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

US valuation of the EQ-5D health states: development and testing of the D1 valuation model.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Statistics notes: Analysing controlled trials with baseline and follow up measurements

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202062

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2012-202062

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41927602&oldid=1929952776"